

par B Aerosol and Intramuscular Prophylaxis of Respiratory Klebsiella pneumoniae Infection in Mice and Squirrel Monkeys 20 **MA06508** Richard F, Berendt, Mark A. Schneider, Marold W. Young Frank R. /Frola (9) Interim rept., 23 Jan 19 (11)16 3M762776A841 (17)00

United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701

The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on the Revision of the Guide for Laboratory Animal Facilities and Care of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care.

Address correspondence to: Dr. R. F. Berendt USAMRIID Fort Detrick, Md. 21701

405-039



JOD

23 January 1979

9 02 21 044

Cleared for public release; distribution unlimited.

SUMMARY

Aerosol administration and intramuscular injection were compared for kanamycin prophylaxis against respiratory <u>Klebsiella pneumoniae</u> infection in both mice and squirrel monkeys. Mice challenged with an LD₉₀ of <u>Klebsiella</u> 0.5, 4, 24, and 48 and 72 hours after aerosol treatment with 27 mg/kg of kanamycin were significantly better protected at all time periods than were mice given 450 mg/kg by IM injection. Squirrel monkeys given 11.25 mg/kg by aerosol were completely protected against <u>Klebsiella</u> challenge at 6 and 24 hours whereas only 1 of 8 monkeys injected IM with the same dose survived at 6 hours and none survived at 24 hours. Antibiotic clearance curves suggested that kanamycin remained in the lungs at higher concentrations and for a longer time after aerosol than after IM treatment.

NTIS		While	Section	
DC		Daff S	ection	
NAT	0112-00			
IS				
	euno://			
list.	AVAn.	and/1	or SPE	CIAL

Gram-negative bacterial pneumonia is an important medical problem in both man and animals. For example, a number of reports have been published in recent years indicating that the incidence of fatal pneumonia due to <u>Klebsiella pneumoniae</u> has increased.¹⁻⁵

We have shown that aerosols of kanamycin are more effective for the treatment of respiratory <u>K</u>. <u>pneumoniae</u> infection in mice than were the same doses of antibiotic given IM.⁶ The greater therapeutic efficacy of aerosols of antibiotic was apparently due to persistence in the lungs as reported by Prokhorova⁷ and Teske and Miller.⁸ Therefore, we also speculated that the administration of single doses of antibiotic by aerosol might be more effective prophylactically than the same dose injected IM. This report presents the results of experiments designed to investigate this possibility both in mice and in a recently developed model using the squirrel monkey.⁹

Materials and methods

<u>Test Organism</u>--Techniques for growing, storing and enhancing the virulence of the A-D strain of type 1 <u>K</u>. <u>pneumoniae</u> have been described previously.⁶ Inocula for infection of experimental animals were prepared as previously described.¹⁰

<u>Test Animals</u>--Monkeys: Healthy, juvenile, male squirrel monkeys (<u>Saimiri sciureus</u>) weighing from 0.5 to 1.0 kg were used. They were housed individually in wire-bar cages and were allowed free access to commercial monkey food and water. Their diet was supplemented with fresh fruit several times weekly.

Mice: Three-week-old, female, white ICR mice [Bla:(ICR)] were used in all experiments. They were housed in plastic cages and fed commercial mouse pellets and water ad libitum.

Infection Techniques--Mice were infected with aerosols in a modified Henderson apparatus, and aerosol sampling was accomplished with all-glass impingers, filled with 20 ml of heart infusion broth.⁶ Estimation of viable bacterial concentration was accomplished by routine procedures of dilution and spreading on trypticase-soy agar plate. These values were then employed for inhaled dosage estimation by previously described calculations.⁶ Infection of monkeys was carried out by the intratracheal (IT) inoculation¹¹ of 7000 <u>K</u>. <u>pneumoniae</u> organisms.

<u>Treatment Techniques</u>--All kanamycin solutions were prepared from 78% kanamycin base^a dissolved in 0.085 M sodium citrate solution adjusted to pH 4.5 with concentrated sulphuric acid.

Aerosol treatment of mice with antibiotics was accomplished with the same Henderson apparatus that was used for infecting the animals.

5

.

1

•

All calculations of inhaled aerosol dose were adjusted to allow for 50% retention of the drug in the lungs as previously described. 6

Aerosol treatment of monkeys required fabrication of a special exposure box. This box (Fig 1) was constructed of acrylic plastic and was divided by a partition into two compartments each 32 cm wide by 25 cm deep by 40 cm high. Perch, exercise bars, and a tray for collection of urine and feces are shown. Four monkeys could thus be exposed to aerosols simultaneously. Aerosols were disseminated into the mixing tube at the top and exhausted through ports near the bottom of each compartment. Ports on the side of the box provided access for collection of aerosol samples to determine aerosol concentration of antibiotic. A port on the top of the box, fitted with a pressure gauge, permitted measurement of pressure differential between the box and the safety cabinet in which it was housed. This pressure differential was equal to 0.5 inch of water so that the exposure box was maintained at a lower pressure than the safety cabinet thus preventing escape of aerosols.

Kanamycin was disseminated into the system from a Collison nebulizer¹² at a rate of 0.22 ml/min. The aerosol particles were entrained in air flowing at a rate of about 40 liters/min. One-half this volume was directed into each exposure compartment. Figure 2 shows the entire aerosol-treatment system including the apparatus required to maintain an equal airflow to the two compartments as well as to equilibrate the air-balance during dissemination and sampling.

All-glass impingers containing 20 ml of distilled water were used for sampling the kanamycin aerosols at the middle of each

exposure period.

<u>Kanamycin Assay</u>--Kanamycin concentrations in impinger fluids and tissues were estimated by microbiological assay as previously described.⁶

7

<u>Experimental Designs</u>--Mice. The initial step consisted of a dose-response experiment to estimate the dose of <u>K</u>. <u>pneumoniae</u> that would kill 90% of challenged mice (LD_{90}) . The LD_{90} dose was calculated from response data by the method of Litchfield and Wilcoxon.¹³

The second phase of the study involved estimation of the dosage of kanamycin given once by aerosol or IM injection that would prevent mortality in 90% of infected animals (ED_{90}) that had been given an LD_{90} dose of <u>Klebsiella</u> 6 hours earlier. The 6-hour period was arbitrarily chosen because the results of earlier studies indicated that aerosol therapy was completely effective at this time. The method of Litchfield and Wilcoxon¹³ was used to calculate the ED_{90} values from the percent survival of mice after treatment with graded doses of antibiotic.

Prophylaxis was investigated by first administering an ED_{90} dose of kanamycin to mice by aerosol or IM injection. Then, at 0.5, 4, 24, 48 and 72 hours, the treated mice were challenged with aerosols of <u>K</u>. <u>pneumoniae</u>. Untreated mice were also infected as controls. This experiment was repeated for a total of four replications. Statistical analysis of the differences between treatment groups was accomplished by Fisher's exact test.¹⁴

The rate of clearance of kanamycin from blood and lungs of IM or aerosol-treated mice was determined by killing 3 mice at each of several selected times and making 25% w/v (lung) or v/v (blood) homogenates in citrate-sulphate buffer, pH 4.5. Tissue was homogenized with a Polytron.^b All homogenates were frozen at -30 C and later were assayed by previously reported procedures.⁶

Monkeys: Since the number of monkeys available was relatively small in comparison to the number of mice employed, many of the preliminary investigations that were carried out in mice were omitted. The IT challenge dose of <u>K</u>. <u>pneumoniae</u> was 7×10^3 . This value was obtained from previously published data.¹⁰ Twelve monkeys were treated by aerosol and 12 by IM injection. At 6 hours, 8 monkeys from each treatment group as well as 4 untreated controls were challenged with <u>K</u>. <u>pneumoniae</u>. The remaining 4 monkeys in each group and 4 more untreated controls were then challenged at 24 hours.

To determine kanamycin clearance patterns, 4 monkeys were given 15 mg/kg by aerosol and 4 received the same dose IM. Two untreated monkeys served as controls. At 6 hours, 2 monkeys from each group and 1 control were bled and then killed with pentobarbital given IV. Homogenates of blood and lungs were prepared and frozen in the same manner as the mouse tissues. The remaining monkeys were killed at 24 hours and samples were taken. Assay of antibiotic was carried out as previously described. Minimum inhibitory and bactericidal concentrations (MIC, MBC) were determined as described by Anderson.¹⁵



Results

Minimum Inhibitory Concentration (MIC) -- The MIC of kanamycin for this strain of <u>Klebsiella</u> was determined to be 0.625 µg/ml. The minimum bactericidal concentration (MBC) was 1.25 µg/ml.

<u>Mice</u>--The number of <u>K</u>. <u>pneumoniae</u> organisms producing a LD_{90} after aerosol exposure was determined by giving aerosol doses ranging from 8 x 10¹ to 8 x 10⁴ cells to 5 groups of 15 mice each. The LD_{90} calculated by extrapolation from the response curve was 1.2 x 10⁵ organisms (approximately 35 LD_{50}). This number of bacteria was employed as a challenge dose in all subsequent experiments.

In order to determine the dosage of kanamycin to use in further studies the ED_{90} therapeutic dose was calculated. One hundred thirtyfive mice were given 35 LD_{50} of <u>K</u>. <u>pneumoniae</u> by aerosol. Six hours later, 4 groups of 15 mice each were injected IM with 0.1 ml of kanamycin solution ranging in concentration from 1.0 to 20 mg/kg of body weight. Similarly, 4 groups of 15 mice each were given from 1.0 to 15.0 mg/kg by aerosol. Fifteen mice were reserved as infected controls; all died. Calculations from dose responses are shown in Table 1. As expected from previous work,⁶ the aerosol route proved much more effective than the IM. The ED_{90} values for the aerosol and IM routes were 27 and 450 mg/kg respectively. These ED_{90} doses were then employed in all subsequent studies.

The prophylactic efficacy of aerosolized kanamycin was then compared to IM injection by administering an ED_{90} dosage of antibiotic to 40 mice for each route. At selected times after the administration of antibiotics groups of 10 mice were challenged with an ED_{90} of <u>K</u>. <u>pneumoniae</u> by aerosol. Ten untreated mice were infected at each time

period as controls. The survival of mice in 4 replicate experiments is shown graphically in Figure 3. All untreated mice died in this experiment. The difference in survival between the 2 routes of antibiotic administration was striking; IM injection protected 83% of the mice against challenge at 0.5 hour, 58% at 4 hours, and less than 10% thereafter; whereas, 100% of the mice were protected at 0.5 and 4 hours after aerosol treatment. Significant protection by aerosol persisted throughout the experiment.

Since kanamycin was more effective prophylactically by aerosol than IM, an experiment was carried out to determine the rate of clearance of antibiotic from blood and lungs. Mice were given an ED_{90} dose of kanamycin by aerosol or IM routes and were killed in groups of 3 at selected intervals ranging from 0.5 to 72 hours after treatment. The concentration of antibiotic in the blood of the IM treated mice killed at 30 minutes averaged 20 µg/ml. No kanamycin was detected in the blood of any other mice. The amount of kanamycin recovered from the lungs of the two groups is shown in Figure 4. Significantly more kanamycin was found in the lungs of the aerosoltreated group than in the IM-treated mice at every time period except at 0.5 hours.

<u>Monkeys</u>--The dose of kanamycin employed by both routes was 11.25 mg/kg. This dose was chosen arbitrarily and was based upon an assessment of the therapeutic efficacy of aerosols for monkeys (unpublished data). Monkeys were exposed by aerosol or injected IM with 11.25 mg/kg and challenged with 7000 <u>K</u>. <u>pneumoniae</u> 6 or 24 hours later. Four untreated controls were challenged at each time. The results of this trial (Table 2) show that aerosol prophylaxis was clearly

superior to IM injection at both time periods. In fact, IM prophylaxis had almost no effect.

In a kanamycin clearance experiment similar to that carried out in mice, the concentration of antibiotic in blood and lungs was determined at 6 and 24 hours; these were the times at which <u>Klebsiella</u> challenge had been carried out. No antibiotic was detected in the blood of any animal at any time. The lung clearance curves are given in Figure 5. Although aérosolized kanamycin was present in much larger quantities and was cleared more slowly than the injected material, it is of interest that a relatively large amount (21µg) was present in the lungs of IM treated monkeys at 6 hours. Despite this concentration, 7 of 8 monkeys died.

Discussion

Aerosols of kanamycin were significantly more effective than IM injection in preventing subsequent respiratory <u>K</u>. <u>pneumoniae</u> infection in both mice and squirrel monkeys. These results seem to be related to the concentration of kanamycin in the lungs. Correlation coefficients (r) calculated on the regression of log percent survival of mice <u>vs</u>. log kanamycin concentrations were 0.80 for both routes of challenge. The r could not be calculated for monkey survival data, but the high concentration of kanamycin in lungs of aerosol-treated monkeys is readily apparent. It is interesting, however, that the concentration of kanamycin in the lungs of IMtreated monkeys at 6 hours was 20 to 30 times the amount required to inhibit replication <u>in vitro</u> (MIC = 0.625 µg/ml), but 7 of 8 monkeys died. A possible explanation may be that the site of persistence of

IN administered kanamycin in the lungs was different than the site of deposition of organisms. In contrast to monkeys, significant protection was seen when mice were challenged 4 hours e^{t} ter IM treatment despite the relatively low tissue concentrations of antibiotic detected at that time.

Persistence of aerosolized kanamycin in the lungs has been shown in mice⁷ and rats;¹⁶ our data seem to extend this list to squirrel monkeys. It has been of interest to us to determine whether the bound kanamycin was active <u>in vivo</u> or whether it dissociated and thereby became active only during the procedures associated with assay. Our prophylaxis data indicate that it is active <u>in vivo</u> in mice and monkeys even though it is bound, presumably to nucleic acid as reported by Potter et al.¹⁷

Our data suggest that single-dose aerosols of kanamycin will protect against subsequent respiratory infection. We have not yet attempted a multiple (i.e., more than one treatment by one route) or combined (i.e., IM and aerosol) regimen, nor have we investigated the problem of superinfection that so often complicates prophylaxis. Nevertheless, it appears that aerosolized antibiotic administration with aminoglycosides may be useful for the prophylaxis of infection in animals and man. Prophylaxis would be especially useful in patients at risk because of preexisting illness.

References

 Graybill JR, Marshall LW, Charache P, Wallace CK, Melvin VB: Nosocomial pneumonia. A continuing major problem. <u>Am Rev Resp Dis</u> 108:1130-1140, 1973.

2. Tillotson JR, Finland M: Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis 119:597-624, 1969.

3. Tillotson JR, Lerner AM: Pneumonias caused by the gram negative bacilli. Medicine 45:65-76, 1966.

4. Good RC, May BD: Respiratory pathogens in monkeys. <u>Infect</u> Immun 3:87-93, 1971.

5. Fegley HC, Sauer RM: Mass treatment of monkeys with antibacterial substances. Ann NY Acad Sci 85:777-784, 1960.

6. Berendt RF, Long GG, Walker JS: Treatment of respiratory <u>Klebsiella pneumoniae</u> infection in mice with aerosols of kanamycin. Antimicrob Agents Chemother 8:585-590, 1975.

7. Prokhorova I I: [Comparative study on efficacy of inhalation and subcutaneous administration of kanamycin in treatment and prophylaxis of experimental pneumonia of albino mice]. <u>Antibiotiki</u> 13:529-533, 1968.

8. Teske RH, Miller SB: Pulmonary absorption and retention of kanamycin after repeated inhalation administration of kanamycin aerosol. <u>Appl Microbiol</u> 19:583-585, 1970.

 Berendt RF, Knutsen GL, Powanda MC: Nonhuman primate model for the study of respiratory <u>Klebsiella pneumoniae</u> infection. Infect Immun 22:275-281, 1978. 10. Berendt RF: Relationship of method of administration to respiratory virulence of <u>Klebsiella pneumoniae</u> for mice and squirrel monkeys. Infect Immun 20:581-583, 1978.

11. Berendt RF, Long GG, Walker JS: Influenza alone and in sequence with pneumonia due to <u>Streptococcus pneumoniae</u> in the squirrel monkey. J <u>Infect Dis</u> 132:689-693, 1975.

12. May KR: The Collison nebulizer: description, performance and application. <u>Aerosol Sci</u> 4:235-243, 1973.

 Litchfield JT Jr, Wilcoxon F: A simplified method of evaluating dose-effect experiments. <u>J Pharmacol Exp Therap</u> 96:99-113, 1949.

14. Bradley JV: <u>Distribution-Free Statistical Tests</u>, Englewood Cliffs, NJ, Prentice-Hall, 1968, pp 195-203.

15. Anderson TG: Testing of susceptibility to antimicrobial agents and assay of antimicrobial agents in body fluids. <u>In</u> Blair JE, Lennette EH, Truant JP(ed), <u>Manual of Clinical Microbiology</u>. Washington, American Society for Microbiology, 1970, pp 299-310.

16. Teske RH, Miller SB: Pulmonary absorption and retention of kanamycin after repeated inhalation administration of kanamycin aerosol. Appl Microbiol 19:583-585, 1970.

17. Potter JL, Matthews LW, Spector S, Lemm J: Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics 36:714-720, 1965.

Route of therapy	^{ED} 50 (mg/kg)	95% Confidence limits	^{ED} 90 (mg/kg)
IM	63.0	37.3-106.5	450
Aerosol	. 1.4	0.6- 3.6	27

TABLE 1--Response of Mice Treated with Kanamycin by the Aerosol or

IM Routes 6 Hours after Infection with <u>Klebsiella</u> pneumoniae

*Challenge dose of <u>K</u>. <u>pneumoniae</u> was 1.2×10^5 organisms (35 LD₅₀)

TABLE 2--Kanamycin Prophylaxis on <u>K</u>. <u>pneumoniae</u> Infection of Squirrel Monkeys

	Resp	onse to	challenge at	
Controls	6 hour	s	24 hour	s
Dead/Total	Dead/Total	P**	Dead/Total	P
8/8	-		-	
-	7/8	0.005	4/4	0.05
-	0/8		0/4	
	Dead/Total	Controls 6 hour Dead/Total Dead/Total 8/8 - - 7/8	Controls 6 hours Dead/Total Dead/Total P** 8/8 - - 7/8 0.005	Dead/Total Dead/Total P** Dead/Total 8/8 - <

* Dose by both routes was 11.25 mg/kg.

1.

 $^{\star\star} {}^2_{\chi}$ test (Yate's correction) aerosol vs. IM response.

Figure Legends

Fig 1--Box for the exposure of monkeys to aerosols of antibiotics (right door removed for clarity). A - Aerosol sampling tube; B left door; C - exercise bar; D - sampling port; E - exhaust port: F - refuse tray; G - perch; H - partition.

Fig 2--Schematic diagram of aerosol therapy system.

Fig 3--Survival of mice exposed to <u>Klebsiella pneumoniae</u> at selected intervals after administration of kanamycin. Asterisks represent rounded probability levels as determined by Fisher's exact test. Fig 4--Concentration of kanamycin in lungs of mice at selected intervals after IM or aerosol exposure.

Fig 5--Concentration of kanamycin in the lungs of squirrel monkeys at 6 and 24 hours after aerosol or IM exposure.





and the second secon

2.18

......







REPORT DOCUMENTATION PAGE	READ INSTRUCTIONS BEFORE COMPLETING FORM
REPORT NUMBER 2. GOVT ACCESSION NO	3. RECIPIENT'S CATALOG NUMBER
TITLE (and Subtitio)	5. TYPE OF REPORT & PERIOD COVERED
AEROSOL AND INTRAMUSCULAR PROPHYLAXIS OF	Interim
RESPIRATORY KLEBSIELLA PNEUMONIAE INFECTION IN	6. PERFORMING ORG. REPORT NUMBER
MICE AND SQUIRREL MONKEYS	
AUTHOR(*) R.F. BERENDT, M. A. SCHNEIDER, H.W. YOUNG: F.R. FROLA	8. CONTRACT OR GRANT NUMBER(*)
PERFORMING ORGANIZATION NAME AND ADDRESS	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
J.S. Army Medical Research Institute of	
Infectious Diseases SGRD-UIA-E	3M762776 A841-00-050
Fort Detrick, Frederick, Maryland 21701	A841-00-030
J.S. Army Medical Research and Development	
Command, Office of the Surgeon General	23 January 1979 13. NUMBER OF PAGES
Department of the Army, Washington, DC 20310	23
. MONITORING AGENCY NAME & ADDRESS(II different from Controlling Office)	15. SECURITY CLASS. (of this report)
	UNCLASSIFIED 154. DECLASSIFICATION/DOWNGRADING
	SCHEDULE
. SUPPLEMENTARY NOTES Reprints bearing assigned AD number will be forwar	
To be submitted for publication in American Journa	
. KEY WORDS (Continue on reverse side if necessary and identify by block number Antibiotic prophylaxis	,)
. KEY WORDS (Continue on reverse side if necessary and identify by block number	

.

Block 20

at 24 hours. Antibiotic clearance curves suggested that kanamycin remained in the lungs at higher concentrations and for a longer time after aerosol than after IM treatment.

SECURITY CLASSIFICATION OF THIS PAGE When Data Fatarad